Alison Moskowitz, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the standard approach to relapsed/refractory lymphoma and the increased use of novel agents such as rituximab and checkpoint inhibitors in second-line therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
